Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development

Epilepsia

Volumn 54, Issue SUPPL.4, 2013, Pages 70-74

  O'Brien, Terence J ^a   Ben Menachem, Elinor ^b   Bertram III, Edward H ^c   Collins, Stephen D ^d   Kokaia, Merab ^e   Lerche, Holger ^f   Klitgaard, Henrik ^g   Staley, Kevin J ^h   Vaudano, Elisabetta ⁱ   Walker, Matthew C ^j   Simonato, Michele ^k  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d NeuroTherapeutics Pharmaceuticals   (United States)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UCB PHARMA   (Belgium)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ Innovative Medicines Initiative (IMI)   (Belgium)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF FERRARA   (Italy)

more..

Author keywords

Antiepilepsy therapies; Multicenter; Preclinical development

Indexed keywords

ANTICONVULSIVE AGENT; NEW DRUG;

ANIMAL; COST CONTROL; DRUG RESISTANCE; DRUG SCREENING; ECONOMICS; EPILEPSY; FINANCIAL MANAGEMENT; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; ANTIEPILEPSY THERAPIES; MULTICENTER; PRECLINICAL DEVELOPMENT; REVIEW;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COST SAVINGS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; MULTICENTER STUDIES AS TOPIC; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

ANTIEPILEPSY THERAPIES; MULTICENTER; PRECLINICAL DEVELOPMENT;

EID: 84891714244     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12300     Document Type: Article

References (6)

1. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J Jr, Loscher W, Noebels JL, Pitkanen A, Stables J, White HS, O'Brien TJ, Simonato M. (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571-582.
2. Galanopoulou AS, Kokaia M, Loeb JA, Nehlig A, Pitkanen A, Rogawski MA, Staley KJ, Whittemore V, Dudek FE (2013) Epilepsy therapy development: Technical and methodological issues in studies with animal models. Epilepsia 54(Suppl. 4):13-23.
3. Kimmelman J, Anderson JA. (2012) Should preclinical studies be registered? Nat Biotechnol 30:488-489.
4. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490:187-191.
5. Prinz F, Schlange T, Asadullah K. (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10:712.
6. Sarter M, Tricklebank M. (2012) Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 11:423-424.